CN101137391B - 重组高效复合干扰素的用途 - Google Patents
重组高效复合干扰素的用途 Download PDFInfo
- Publication number
- CN101137391B CN101137391B CN2006800077331A CN200680007733A CN101137391B CN 101137391 B CN101137391 B CN 101137391B CN 2006800077331 A CN2006800077331 A CN 2006800077331A CN 200680007733 A CN200680007733 A CN 200680007733A CN 101137391 B CN101137391 B CN 101137391B
- Authority
- CN
- China
- Prior art keywords
- rsifn
- interferon
- virus
- equivalent
- provides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65992505P | 2005-03-09 | 2005-03-09 | |
US60/659,925 | 2005-03-09 | ||
PCT/IB2006/002340 WO2006134497A2 (en) | 2005-03-09 | 2006-03-09 | Uses of recombinant super-compound interferons |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101137391A CN101137391A (zh) | 2008-03-05 |
CN101137391B true CN101137391B (zh) | 2012-07-18 |
Family
ID=37532680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800077331A Active CN101137391B (zh) | 2005-03-09 | 2006-03-09 | 重组高效复合干扰素的用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20080124302A1 (zh) |
EP (3) | EP2537527A3 (zh) |
JP (1) | JP5209462B2 (zh) |
KR (1) | KR101329878B1 (zh) |
CN (1) | CN101137391B (zh) |
AU (1) | AU2006257286B2 (zh) |
CA (1) | CA2597317C (zh) |
MY (1) | MY167668A (zh) |
TW (1) | TWI380993B (zh) |
WO (1) | WO2006134497A2 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
US8551469B2 (en) | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
US7585647B2 (en) | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
CN101525381B (zh) * | 2008-03-04 | 2012-04-18 | 北京百川飞虹生物科技有限公司 | 一种重组复合干扰素及其表达载体的构建和表达 |
CN102101886A (zh) * | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | 构象改变的重组干扰素晶体、其三维结构及应用 |
KR101871851B1 (ko) | 2011-12-22 | 2018-06-28 | 두산공작기계 주식회사 | 공작기계용 도어의 이탈 방지장치 |
TWI718086B (zh) * | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
CN104415325A (zh) * | 2013-08-27 | 2015-03-18 | 天士力制药集团股份有限公司 | 一种重组人干扰素β-1b冻干制剂及其制备方法 |
EP3068420B1 (en) * | 2013-11-13 | 2019-10-23 | Superlab Far East Limited | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
RU2585695C1 (ru) * | 2015-03-12 | 2016-06-10 | Закрытое акционерное общество "Вектор-Медика" (ЗАО "Вектор-Медика") | Способ ингибирования инфекционной активности вируса эбола в эксперименте |
CN111363726A (zh) * | 2018-12-26 | 2020-07-03 | 上海元宋生物技术有限公司 | 表达干扰素的溶瘤病毒及其应用 |
CN111658779A (zh) * | 2020-06-22 | 2020-09-15 | 四川大学华西医院 | 治疗新型冠状病毒肺炎的联合用药物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1375502A (zh) * | 2001-10-25 | 2002-10-23 | 南京药科大学 | 聚乙二醇修饰重组人干扰素 |
AU2003248419A1 (en) * | 2001-02-28 | 2003-11-06 | Superlab Far East Limited | Recombinant super-compound interferon |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4672108A (en) * | 1981-12-07 | 1987-06-09 | Hoffmann-La Roche Inc. | Crystalline human leukocyte interferon |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
US4681930A (en) * | 1983-09-20 | 1987-07-21 | Hoffmann-La Roche Inc. | Immune interferon and a method for its extraction and purification |
US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
CA2094275C (en) * | 1990-10-17 | 2003-06-03 | Lawrence M. Blatt | Methods and compositions for the treatment of cell proliferation disorders |
US5441734A (en) * | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
EP0626448A3 (de) * | 1993-05-26 | 1998-01-14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verfahren zur Herstellung und Reinigung von alpha-Interferon |
JP4709333B2 (ja) * | 1995-10-13 | 2011-06-22 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | ホスホパンテテイニルトランスフェラーゼおよびその使用 |
US5972331A (en) * | 1995-12-22 | 1999-10-26 | Schering Corporation | Crystalline interferon alpha for pulmonary delivery and method for producing the same |
US5874304A (en) * | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5980884A (en) * | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
US6532437B1 (en) * | 1996-10-23 | 2003-03-11 | Cornell Research Foundation, Inc. | Crystalline frap complex |
US6114145A (en) * | 1997-12-05 | 2000-09-05 | Human Genome Sciences, Inc. | Synferon, a synthetic interferon |
US6087478A (en) * | 1998-01-23 | 2000-07-11 | The Rockefeller University | Crystal of the N-terminal domain of a STAT protein and methods of use thereof |
DE10037111A1 (de) * | 2000-07-27 | 2002-02-07 | Boehringer Ingelheim Int | Herstellung eines rekombinanten Proteins in einer prokaryontischen Wirtszelle |
US20020043262A1 (en) * | 2000-08-22 | 2002-04-18 | Alan Langford | Spray device |
US7544354B2 (en) * | 2000-10-27 | 2009-06-09 | Novartis Vaccines And Diagnostics | Methods of protein purification and recovery |
US20060035327A1 (en) * | 2001-02-28 | 2006-02-16 | Guangwen Wei | Recombinant super-compound interferon and uses thereof |
US6546074B1 (en) * | 2001-03-27 | 2003-04-08 | Astex Technology Limited | Protein crystal structure and method for identifying protein modulators |
IL161901A0 (en) * | 2001-11-14 | 2005-11-20 | Biocryst Pharmaceuticals Inc A | Nucleosides, preparation thereof and use as inhibiDevice for the reading and the signalling of environmental parameters tors of rna viral polymerases |
US20050021976A1 (en) | 2003-06-23 | 2005-01-27 | Nokia Corporation | Systems and methods for controlling access to an event |
CN1202861C (zh) * | 2003-07-18 | 2005-05-25 | 中国科学院微生物研究所 | 复合干扰素在治疗sars疾病中的用途 |
CA2535982C (en) | 2003-08-28 | 2016-11-29 | Huiyangtech (Usa), Inc. | Uses of interferons with altered spatial structure |
WO2005113592A2 (en) * | 2004-05-19 | 2005-12-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
-
2006
- 2006-03-09 JP JP2008500294A patent/JP5209462B2/ja active Active
- 2006-03-09 MY MYPI20061015A patent/MY167668A/en unknown
- 2006-03-09 WO PCT/IB2006/002340 patent/WO2006134497A2/en not_active Application Discontinuation
- 2006-03-09 EP EP12184773A patent/EP2537527A3/en not_active Withdrawn
- 2006-03-09 AU AU2006257286A patent/AU2006257286B2/en active Active
- 2006-03-09 CN CN2006800077331A patent/CN101137391B/zh active Active
- 2006-03-09 US US11/817,926 patent/US20080124302A1/en not_active Abandoned
- 2006-03-09 KR KR1020077020614A patent/KR101329878B1/ko active IP Right Grant
- 2006-03-09 EP EP06795349A patent/EP1868636A4/en not_active Withdrawn
- 2006-03-09 TW TW095107930A patent/TWI380993B/zh active
- 2006-03-09 CA CA2597317A patent/CA2597317C/en active Active
- 2006-03-09 EP EP14161329.9A patent/EP2749290A3/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003248419A1 (en) * | 2001-02-28 | 2003-11-06 | Superlab Far East Limited | Recombinant super-compound interferon |
CN1375502A (zh) * | 2001-10-25 | 2002-10-23 | 南京药科大学 | 聚乙二醇修饰重组人干扰素 |
Non-Patent Citations (1)
Title |
---|
同上. |
Also Published As
Publication number | Publication date |
---|---|
EP1868636A2 (en) | 2007-12-26 |
EP2537527A3 (en) | 2013-02-20 |
EP2749290A3 (en) | 2015-02-18 |
KR20070108904A (ko) | 2007-11-13 |
US20080124302A1 (en) | 2008-05-29 |
EP2749290A2 (en) | 2014-07-02 |
AU2006257286B2 (en) | 2012-08-16 |
AU2006257286A1 (en) | 2006-12-21 |
EP1868636A4 (en) | 2012-03-28 |
TW200640943A (en) | 2006-12-01 |
JP2008532995A (ja) | 2008-08-21 |
KR101329878B1 (ko) | 2013-11-22 |
JP5209462B2 (ja) | 2013-06-12 |
WO2006134497A3 (en) | 2007-08-30 |
MY167668A (en) | 2018-09-21 |
CN101137391A (zh) | 2008-03-05 |
CA2597317A1 (en) | 2006-12-21 |
EP2537527A2 (en) | 2012-12-26 |
CA2597317C (en) | 2018-01-02 |
WO2006134497A2 (en) | 2006-12-21 |
TWI380993B (zh) | 2013-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101137391B (zh) | 重组高效复合干扰素的用途 | |
CN106282216B (zh) | 一种重组长效鸡干扰素α的制备方法 | |
CN107074967A (zh) | 白介素‑2/白介素‑2受体α融合蛋白和使用方法 | |
CN102041263B (zh) | 鸡α干扰素/白细胞介素2嵌合基因 | |
Wang et al. | Molecular characterization and biological functioning of interleukin-8 in Siberian sturgeon (Acipenser baeri) | |
CN102153657A (zh) | IL-24-Tat PTD融合蛋白及其构建方法和应用 | |
CN1611604A (zh) | 猪α-干扰素的基因合成、表达载体构建及产物的制法 | |
CN106552259A (zh) | 一种融合蛋白及其治疗疾病的用途 | |
CN101643749A (zh) | 腺相关病毒载体及其制备方法和应用 | |
CN104940955B (zh) | 一种microRNA在制备治疗流感的药物中的应用 | |
CN107513107A (zh) | 抗肿瘤融合蛋白及其制法和应用 | |
CN104531691A (zh) | 一种获取牛干扰素α的基因的引物、重组牛干扰素α的制备方法 | |
CN101688205B (zh) | 抗肿瘤药物、药剂、组合物及其用途 | |
CN111094324A (zh) | 一种溶瘤病毒、合成dna序列及其应用 | |
CN110101843A (zh) | 一种抗肿瘤蛋白质及其应用 | |
CN102079784A (zh) | 一种犬α干扰素突变体 | |
CN110684768B (zh) | 一种基于模式识别受体配体的鸭天然免疫增强剂 | |
CN103865899A (zh) | 具有vegfr2/kdr受体特异性的融合毒素及其编码基因与应用 | |
CN1167712C (zh) | 一种白细胞介素11类似物 | |
CN104388452B (zh) | 一种犬干扰素α融合蛋白及其制备方法和应用 | |
CN1800215A (zh) | 一种预防和治疗日本血吸虫感染的相关基因和蛋白质及其用途 | |
CN103409384A (zh) | 一种具有抗病毒活性的对虾蛋白及其应用 | |
CN101328475B (zh) | 核酸分子nrn1sr1及其在制备抗癌药物中的应用 | |
CN116790580A (zh) | 一种溶瘤病毒来源的rna及其用途 | |
CN111154755A (zh) | 一种双链寡核苷酸dna及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SICHUAN HUIYANG LIFE SCIENCE AND TECHNOLOGY CORP. Free format text: FORMER OWNER: WEI GUANGWEN Effective date: 20130107 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610000 CHENGDU, SICHUAN PROVINCE TO: 610063 CHENGDU, SICHUAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130107 Address after: 610063, Chengdu, Sichuan, Jinjiang District three color road 163, Yinhai core block, room 402 Patentee after: Sichuan Huiyang Life Engineering Co., Ltd. Address before: 610000 Sichuan Province, Chengdu City Jade Road No. 8 Patentee before: Wei Guangwen |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151223 Address after: The British Virgin Islands of Tortola Patentee after: SUPERLAB FAR EAST LTD. Address before: 610063, Chengdu, Sichuan, Jinjiang District three color road 163, Yinhai core block, room 402 Patentee before: Sichuan Huiyang Life Engineering Co., Ltd. |